InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,299.09
(
-0.62%
)
Post# of 252494
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

drbio45

Send PM Follow Ignore
Followers 36
Posts 3185
Boards Moderated 0
Alias Born 10/18/2003

drbio45

Re: bladerunner1717 post# 84070

Thursday, 09/24/2009 6:37:05 PM

Thursday, September 24, 2009 6:37:05 PM

Post# of 252494
Dr. Ron Garren, a biotech newsletter writer and a practising oncologist, is also on board with ARIA. He says the 534 results are outstanding and it is sure to find a niche market in resistant CML


Let me get this straight. He is on the board of Ariad, and he is telling his subsribers that the results of the 534 trial are outstanding. That sounds like inside information to me. I think he is smarter than that.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up